Showing results (181-190 of 258) with videos related to

Sort By:
Pageof 26
Data in Brief|December 28, 2020
Genotyping data of routinely processed matched primary/metastatic tumor samplesVassiliki Kotoula, Kyriakos Chatzopoulos, Kyriaki Papadopoulou, et al.
Nature Communications|January 7, 2017
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinomaJin Zhou, Zhong Wu, Gabrielle Wong, et al.
BMC Cancer|May 10, 2015
Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancerDimitrios Pectasides, Vasilios Karavasilis, George Papaxoinis, et al.
Oncology Reports|October 26, 2011
Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) studyDimitrios Pectasides, George Papaxoinis, Vassiliki Kotoula, et al.
Oncology|January 12, 2008
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyOlympia Tzaida, Helen Gogas, Urania Dafni, et al.
Urologic Oncology|August 30, 2022
Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimensKyriaki Papadopoulou, Georgia-Angeliki Koliou, Dimitrios Tsimiliotis, et al.
Targeted Oncology|November 30, 2018
Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II StudyVasilios Karavasilis, Epaminontas Samantas, Georgia-Angeliki Koliou, et al.
Clinical Breast Cancer|May 22, 2012
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expressionEvangelia Razis, Konstantine T Kalogeras, Vassiliki Kotoula, et al.
Anticancer Research|April 30, 2016
Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast CancerSotirios Lakis, Stefanos Dimoudis, Vassiliki Kotoula, et al.
Breast Cancer Research and Treatment|June 28, 2005
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology GroupGeorge Fountzilas, Dimitrios Pectasides, Anna Kalogera-Fountzila, et al.
Pageof 26